Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P333: Associations between multiple immunosuppressive treatments before surgery and surgical morbidity in patients with ulcerative colitis during the era of biologics

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Uchino*1, H. Ikeuchi1, T. Bando1, T. Chohno1, H. Sasaki1, Y. Horio1, R. Kuwahara1, T. Minagawa1, Y. Goto1

1Hyogo College of Medicine, Inflammatory Bowel Disease, Nishinomiya, Japan

P334: Chromoendoscopy is superior to white light endoscopy for the detection of advanced colonic neoplasia in patients with inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

K. O. Kim*1,2, M. Chiorean2

1Yeungnam University College of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Daegu, South Korea, 2Virginia Mason Medical Center, Digestive Disease Institute, Seattle, USA

P335: Long-term follow-up of switching from original infliximab to infliximab biosimilar: real-world data

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Guerra Veloz*1, M. Belvis Jimenez1, T. Valdes Delgado1, L. Castro Laria1, B. Maldonado Pérez1, A. Benítez Roldán1, R. Perea Amarillo1, V. Merino Bohorquez2, M. A. Calleja Hernandez2, A. Caunedo Álvarez1, A. Vilches Arenas3, F. Argüelles-Arias1

1Virgen Macarena Hospital, Gastroenterology, Seville, Spain, 2Virgen Macarena Hospital, Pharmacy Unit, Seville, Spain, 3Virgen Macarena Hospital, Preventive Medicine and Public Health, Seville, Spain

P336: Behavioural treatment options for psychological comorbidities in patients with inflammatory bowel disease: a systematic literature review

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Keefer1, R. Cheung*2, M. Bernauer3, D. Patel2, M. Dubinsky1

1Icahn School of Medicine at Mount Sinai, New York City, USA, 2Pfizer Inc., New York City, USA, 3Pharmerit International, Bethesda, USA

P337: Switching from originator infliximab to CT-P13: single-centre experience from the UK

ECCO '19 Copenhagen

Year: 2019
Authors:

A. P. Bhandare*1, B. Crooks1, G. B. Nigam1, J. K. Limdi1,2

1Pennine Acute Hospitals Trust, Gastroenterology, Manchester, UK, 2University of Manchester, Institute of Inflammation and Repair, Manchester, UK

P338: Long-term complications in patients with fistulising Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Vuyyuru*1, S. Kedia1, P. Sahu1, S. Bopanna1, S. Jain1, G. Makharia1, V. Ahuja1

1All India Institute Of Medical Sciences, Gastroenterology, New Delhi, India

P339: Application of Bayesian modelling with infliximab to determine optimal patient-specific regimens

ECCO '19 Copenhagen

Year: 2019
Authors:

T. E. Ritter*1, H. E. SarlesJr2, R. C. McLeay3, L. J. Van Anglen4, C. P. Schroeder4, T. C. Hardin4

1Texas Digestive Disease Consultants, PA, Clinical Research and Education, Southlake, TX, USA, 2Digestive Health Associates of Texas, PA, DHAT Research Institute, Richardson, TX, USA, 3DoseMe, Brisbane, Qld, Australia, 4Healix, Pharmacy and Clinical Research, Sugar Land, TX, USA

P340: Vedolizumab in the treatment of chronic refractory pouchitis: a systematic review

ECCO '19 Copenhagen

Year: 2019
Authors:

W-C. Lim*1, H. Lin1

1Tan Tock Seng Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore

P341: Identification and management of psychological distress after stoma surgery: a qualitative study of patients and healthcare professionals

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Polidano*1, C. A. Chew-Graham1,2,3, A. D. Farmer4,5, B. Saunders1

1Keele University, Research Institute for Primary Care and Health Sciences, Newcastle under Lyme, UK, 2West Midlands Collaboration for Leadership in Applied Health Research and Care, Newcastle under Lyme, UK, 3Midlands Partnership Foundation Trust, Stafford, UK, 4Keele University, Institute of Applied Clinical Sciences, Newcastle under Lyme, UK, 5University Hospitals of North Midlands NHS Trust,, Department of Gastroenterology, Stoke-on-Trent, UK

P342: A population pharmacokinetic model to support therapeutic drug monitoring during vedolizumab therapy

ECCO '19 Copenhagen

Year: 2019
Authors:

E. Dreesen*1, B. Verstockt2,3, S. Vermeire2,3, M. Ferrante2,3, A. Gils1

1University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 2University of Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, 3University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium

P343: Efficacy of ustekinumab in Crohn’s disease at maintenance Week 56: IM-UNITI study

ECCO '19 Copenhagen

Year: 2019
Authors:

W. J. Sandborn*1, B. Sands2, J-F. Colombel2, C. Gasink3, R. Patel4, D. Jacobstein5, L-L. Gao5, S. Ghosh6, S. Targan7, W. De Villiers8, S. B. Hanauer9, P. Rutgeerts10, B. Feagan11

1University of California San Diego, La Jolla, USA, 2Icahn School of Medicine at Mt Sinai, New York, USA, 3Janssen Scientific Affairs, LLC, Horsham, USA, 4Janssen Pharmaceuticals, Horsham, USA, 5Janssen Research and Development, LLC, Spring House, USA, 6University of Birmingham, Birmingham, UK, 7Cedars-Sinai Medical Center, Los Angeles, USA, 8Stellenbosch University, Stellenbosch, South Africa, 9Northwestern University, Feinberg School of Medicine, Chicago, USA, 10University Hospital Gasthuisberg, Leuven, Belgium, 11Robarts Clinical Trials, Robarts Research Institute, Western University, London, Canada

P344: Real-world effectiveness of tofacitinib in ulcerative colitis: a multi-centre study

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Ungaro*1, M. Fenster1, C. Dimopoulos1, A. Patel2, P. Deepak3, G. Syal4, A. Yarur5, R. Hirten1, G. Christophi3, A. Khatiwada3, B. Lin5, J-F. Colombel1, C. Ha4, R. Weisshof6, P. Beniwal-Patel5, B. Cohen1, J. Pekow6

1Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, USA, 2Brooke Army Medical Center, Fort Sam Houston, USA, 3Division of Gastroenterology, Washington University in Saint Louis, Saint Louis, USA, 4Cedars-Sinai Medical Center, Los Angeles, USA, 5Medical College of Wisconsin, Milwaukee, USA, 6Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, USA

P345: Risk of long-term post-operative recurrence (POR) in Crohn’s disease patients with a first postoperative normal endoscopic assessment under thiopurine prevention

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Mañosa1,2, M. Puig1, P. F. Torres1, F. Cañete1, J. Troya3, M. Calafat1, D. Parés3, E. Cabré1,2, E. Domènech1,2

1Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain, 2Ciberehd, Madrid, Spain, 3Hospital Universitari Germans Trias i Pujol, Surgery, Badalona, Spain

P346: Small bowel permeability improves with nutritional therapy in mild-to-moderate active paediatric Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

E. Wine*1, G. Abitbol2, A. Assa3, R. Sigall Boneh4, R. Shaoul5, M. Kori6, S. Cohen7, S. Peleg8, H. Shamaly9, A. On10, P. Millman11, L. Abramas4, T. Ziv Baran12, J. Van Limbergen13, A. Levine4,12

1University of Alberta, Pediatrics, Edmonton, Canada, 2Shaarey Zedek Hospital, Jerusalem, Israel, 3Schneider Medical Center, Petach Tikva, Israel, 4Wolfson Medical Center, Holon, Israel, 5Meyer Hospital, Haifa, Israel, 6Kaplan Hospital, Rehovot, Israel, 7Dana Children’s Hospital, Tel Aviv, Israel, 8HaEmek Hospital, Afula, Israel, 9French Hospital, Nazareth, Israel, 10Poriah Hospital, Tiberias, Israel, 11Hadassah Hospital, Jerusalem, Israel, 12Tel Aviv University, Tel Aviv, Israel, 13IWK Center and Dalhousie University, Halifax, Canada

P347: New-onset autoimmune disorders, primarily psoriasis, in anti-TNF biologic exposed paediatric patients: the DEVELOP experience

ECCO '19 Copenhagen

Year: 2019
Authors:

G. Veereman*1, A. Griffiths2, R. Colletti3, B. Gold4, J. Izanec5, C. Busse6, Y. Wang7, J. Escher8

1Universitair Ziekenhuis, Vrije Uniuversiteit Brussel, Brussel, Belgium, 2Hospital For Sick Children, Toronto, Canada, 3University of Vermont Children’s Hospital, Burlington, USA, 4Children's Center for Digestive Health Care, LLC, Atlanta, USA, 5Janssen Scientific Affairs, LLC, Horsham, USA, 6Janssen Pharmaceuticals, Horsham, PA, Horsham, USA, 7Janssen Research and Development, LLC, Spring House, USA, 8Erasmus Mc-Sophia Children's Hospital, Rotterdam, The Netherlands

P348: Correlation between Mayo endoscopic score and validated histological score in ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Shah*1, U. Dutta1, A. Das2, V. Sharma1, H. Madhavdhare1, N. Dhaka1, S. K. Sinha1, R. Kochhar1

1PGIMER, Gastroenterology, Chandigarh, India, 2PGIMER, Pathology, Chandigarh, India

P349: Cyclosporine has no clinically meaningful effect on pharmacokinetics (PK) of BMS-986165, an oral selective tyrosine kinase 2 (TYK2) inhibitor, in healthy subjects

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Chimalakonda*1, J. JonesIII2, R. Dockens1, J. Throup1, S. Banerjee1, I. Girgis1

1Bristol-Myers Squibb, Princeton, USA, 2PRA Health Sciences, Blue Bell, USA

P350: Real-world data regarding treatment of ulcerative colitis patients with golimumab in Switzerland

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Perrig1, J-B. Rossel2, L. Biedermann1, P. Schreiner1, R. Roth1, J. Zeitz3, T. Greuter1, S. Vavricka4, N. Krupka5, P. Juillerat5, G. Rogler1, B. Misselwitz*5

1University Hospital Zurich and Zurich University, Gastroenterology and Hepatology, Zurich, Switzerland, 2University of Lausanne, Institute of Social and Preventive Medicine, Lausanne, Switzerland, 3Center of Gastroenterology, Klinik Hirslanden, Zurich, Switzerland, 4Center of Gastroenterology and Hepatology, Zurich, Switzerland, 5Inselspital and Bern University, Department of Visceral Surgery and Medicin, Bern, Switzerland

P351: MRI outcomes in perianal fistulising Crohn’s disease following anti-TNF-α therapy: a systematic review and meta-analysis

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Lee*1, N. Ding2

1St Vincent's Hospital, Melbourne, Clinical School, Fitzroy, Australia, 2St Vincent's Hospital, Melbourne, Gastroenterology, Fitzroy, Australia

P352: TDM of infliximab in IBD-patients: which pharmacokinetic marker to use?

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Berends*1,2, R. Mathôt1, A. Strik2, A. De Vries3, M. Löwenberg2, G. D'Haens2

1Amsterdam UMC - location AMC, Hospital Pharmacy, Amsterdam, The Netherlands, 2Amsterdam UMC - location AMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 3Sanquin Diagnostic Services, Biologics Lab, Bioanalysis, Amsterdam, The Netherlands